Accuray Gains On Radixact Unit, Solid Geographical Foothold
Zacks Investment Research | Mar 12, 2018 10:52PM ET
Accuray Incorporated (ARAY) gains from strong demand for Radixact platform. Solid growth in European and APAC regions also holds promise. Lately, contributions in order performance from the EMEA and Japan regions have also been solid. The stock has a Zacks Rank #2 (Buy).
Radixact is one of the company’s latest devices, which contributed to revenues in the second quarter of fiscal 2018 results. The Radixact system comprised 70% of all TomoTherapy orders. More than 25 Radixact units have been recognized since the product launch.
Further, the system is being accepted as a true workhorse product in the market, courtesy of its significantly improved product performance, functional efficacies and broad case mix versatility.
Growing adoption of non-surgical treatment options, successful execution of restructuring plans and accretive acquisitions are other positives.
Recently, Accuray announced the launch of its precision treatment planning system. The system leverages on the company’s flagship Radixact and CyberKnife system platforms. The company plans to build on this technology with Precision 2.0 upgrade by fiscal 2018. This will significantly improve treatment speed and overall throughput of the existing CyberKnife system.
Accuray also announced 510(k) clearance for the new IBMS data management system for TomoTherapy. It is a centralized database that shares and makes data accessible between multiple accurate systems, adding flexibility and improving workflow efficiency in the radiation therapy department. Studies have proved that CyberKnife provides long-lasting pain relief procedures for Trigeminal Neuralgia patients.
Further, the Heidelberg University Hospital in Heidelberg, Germany and Oscar Lambret Cancer Center in Lille, France are the first in the world to connect with these two systems.
Dull Price Performance
In the past year, Accuray has underperformed its Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.